Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
| Autor: | Tibau Martorell, Ariadna, López Vilaró, Laura, Pérez Olabarria, Maitane, Vázquez, Tania, Pons, Cristina, Gich, Ignasi, Alonso, Carmen, Ojeda, Belén, Ramon y Cajal, Teresa, Lerma Puertas, Enrique, Barnadas i Molins, Agustí, Escuin i Borràs, Daniel, Universitat Autònoma de Barcelona |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
DFS disease-free survival ER estrogen receptor Receptor ErbB-2 medicine.medical_treatment FISH fluorescence in situ hybridization Chromosome Duplication Gene duplication Anthracyclines HER2 human epidermal growth factor receptor 2 Poly-ADP-Ribose Binding Proteins In Situ Hybridization Fluorescence Neoadjuvant therapy TOP2A topoisomerase II alpha Aged 80 and over Antibiotics Antineoplastic medicine.diagnostic_test pCR pathologic complete response Middle Aged Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Neoadjuvant Therapy DNA-Binding Proteins Treatment Outcome EC-D epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) followed by docetaxel (100 mg/m2) Female Pcr pathologic complete response Adult Anthracycline Centromere Chromogenic in situ hybridization Breast Neoplasms Biology lcsh:RC254-282 Article OS overall survival Breast cancer Antigens Neoplasm medicine Humans CISH Aged Retrospective Studies EC-D epirubicin (90 mg/m 2) and cyclophosphamide (600 mg/m 2) followed by docetaxel (100 mg/m 2) Chemotherapy CEP17 chromosome 17 centromere enumeration probe Gene Amplification CISH chromogenic in situ hybridization PR progesterone receptor medicine.disease Survival Analysis HR hazard ratio FEC75 fluorouracil (600 mg/m2) epirubicin (75 mg/m2) and cyclophosphamide (600 mg/m2) CI confidence interval OR odds ratio DNA Topoisomerases Type II FEC75 fluorouracil (600 mg/m 2) epirubicin (75 mg/m 2) and cyclophosphamide (600 mg/m 2) Cancer research Chromosomes Human Pair 17 Fluorescence in situ hybridization |
| Zdroj: | Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 10, Pp 861-867 (2014) Neoplasia (New York, N.Y.) Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona NEOPLASIA r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 1476-5586 |
| DOI: | 10.1016/j.neo.2014.08.012 |
| Popis: | Altres ajuts: RTICC RD12-0036-0076 Human epidermal growth factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) genes have been proposed as predictive biomarkers of sensitivity to anthracycline chemotherapy. Recently, chromosome 17 centromere enumeration probe (CEP17) duplication has also been associated with increased responsiveness to anthracyclines. However, reports are conflicting and none of these tumor markers can yet be considered a clinically reliable predictor of response to anthracyclines. We studied the association of TOP2A gene alterations, HER2 gene amplification, and CEP17 duplication with response to anthracycline-based neoadjuvant chemotherapy in 140 patients with operable or locally advanced breast cancer. HER2 was tested by fluorescence in situ hybridization and TOP2A and CEP17 by chromogenic in situ hybridization. Thirteen patients (9.3%) achieved pathologic complete response (pCR). HER2 amplification was present in 24 (17.5%) of the tumors. TOP2A amplification occurred in seven tumors (5.1%). CEP17 duplication was detected in 13 patients (9.5%). CEP17 duplication correlated with a higher rate of pCR [odds ratio (OR) 6.55, 95% confidence interval (95% CI) 1.25-34.29, P =.026], and analysis of TOP2A amplification showed a trend bordering on statistical significance (OR 6.97, 95% CI 0.96-50.12, P =.054). TOP2A amplification and CEP17 duplication combined were strongly associated with pCR (OR 6.71, 95% CI 1.66-27.01, P =.007). HER2 amplification did not correlate with pCR. Our results suggest that CEP17 duplication predicts pCR to primary anthracycline-based chemotherapy. CEP17 duplication, TOP2A amplifications, and HER2 amplifications were not associated with prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|